AML

>

Latest News

LYT-200 Gains FDA Orphan Drug Designation in Acute Myeloid Leukemia
LYT-200 Gains FDA Orphan Drug Designation in Acute Myeloid Leukemia

March 13th 2024

The FDA granted orphan drug designation to LYT-200, a drug being investigated for treating acute myeloid leukemia.

FDA Lifts Clinical Hold on CAR T Study in AML
FDA Lifts Clinical Hold on CAR T Study in AML

February 12th 2024

FDA Halts Clinical Studies of Magrolimab in AML, MDS
FDA Halts Clinical Studies of Magrolimab in AML, MDS

February 7th 2024

Beat AML Study Highlights Influential Factors in AML Treatment
Beat AML Study Highlights Influential Factors in AML Treatment

February 6th 2024

DSP-5336 is Well-Tolerated in R/R MLLr and NMP1-Mutant Acute Leukemia
DSP-5336 is Well-Tolerated in R/R MLLr and NMP1-Mutant Acute Leukemia

January 30th 2024

Video Series
Video Interviews

More News